Myocardin Inhibitors
The class of Myocardin inhibitors encompasses a diverse range of chemical compounds strategically designed to modulate Myocardin activity either directly or indirectly through intricate cellular pathways. Y-27632, a selective ROCK inhibitor, acts indirectly by disrupting the RhoA/ROCK pathway, reducing Myocardin activity and influencing cellular processes regulated by Myocardin-mediated transcriptional regulation. CCG-222740 stands out as a direct inhibitor of Myocardin, disrupting its interaction with the serum response factor (SRF). This small molecule impedes the formation of the Myocardin-SRF complex, impairing Myocardin's transcriptional activity and directly influencing gene expression processes governed by Myocardin-SRF regulatory networks. SMIFH2 serves as an indirect inhibitor of Myocardin by modulating the actin cytoskeleton. As an inhibitor of formin homology 2 domain (FH2)-containing proteins, SMIFH2 disrupts actin dynamics, influencing Myocardin's nuclear translocation and activity. This interference alters Myocardin-mediated transcriptional regulation, thereby impacting cellular processes regulated by Myocardin-induced gene expression.
CC-401, another indirect inhibitor, targets the TGF-β/Smad3 pathway. By inhibiting TGF-β receptor type I (TGFBR1) activity, CC-401 interferes with Smad3 phosphorylation and nuclear translocation, reducing its interaction with Myocardin. CK-666, an Arp2/3 complex inhibitor, serves as both a direct and indirect inhibitor of Myocardin. By disrupting actin polymerization, CK-666 influences Myocardin's nuclear translocation and activity, thereby impacting cellular processes regulated by Myocardin-induced gene expression. Blebbistatin, acting as a selective inhibitor of myosin II ATPase activity, indirectly inhibits Myocardin by modulating the actin cytoskeleton. This interference disrupts actin dynamics, influencing Myocardin's nuclear translocation and activity, ultimately impacting cellular processes regulated by Myocardin-induced gene expression. A83-01, functioning as an indirect inhibitor, targets the TGF-β/Smad2 pathway. By inhibiting TGF-β receptor type I (TGFBR1) activity, A83-01 interferes with Smad2 phosphorylation and nuclear translocation, reducing its interaction with Myocardin.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 inhibits Myocardin indirectly by targeting the RhoA/ROCK pathway. As a selective ROCK inhibitor, Y-27632 disrupts RhoA-mediated signaling, reducing Myocardin activity. This interference hampers Myocardin's ability to regulate smooth muscle gene expression, influencing cellular processes modulated by Myocardin-mediated transcriptional regulation. | ||||||
SMIFH2 | 340316-62-3 | sc-507273 | 5 mg | $140.00 | ||
SMIFH2 serves as an indirect inhibitor of Myocardin by modulating the actin cytoskeleton. Acting as an inhibitor of formin homology 2 domain (FH2)-containing proteins, SMIFH2 disrupts actin dynamics, influencing Myocardin's nuclear translocation and activity. This interference alters Myocardin-mediated transcriptional regulation, thereby impacting cellular processes regulated by Myocardin-induced gene expression. | ||||||
CC-401 | 395104-30-0 | sc-364748 sc-364748A | 2 mg 10 mg | $331.00 $1060.00 | 4 | |
CC-401 functions as an indirect inhibitor of Myocardin by targeting the TGF-β/Smad3 pathway. As a TGF-β receptor type I (TGFBR1) inhibitor, CC-401 interferes with Smad3 phosphorylation and nuclear translocation, reducing its interaction with Myocardin. This modulation limits Myocardin's coactivation of Smad3-mediated transcription, influencing cellular processes governed by the TGF-β/Smad3/Myocardin regulatory axis. | ||||||
CCG-1423 | 285986-88-1 | sc-205241 sc-205241A | 1 mg 5 mg | $30.00 $90.00 | 8 | |
CCG-1423 acts as a direct inhibitor of Myocardin by disrupting its interaction with the serum response factor (SRF). This small molecule inhibits the Myocardin-SRF complex formation, impairing Myocardin's transcriptional activity. Consequently, CCG-1423-induced inhibition directly influences Myocardin-mediated gene expression, impacting cellular processes governed by Myocardin-SRF regulatory networks. | ||||||
CK 666 | 442633-00-3 | sc-361151 sc-361151A | 10 mg 50 mg | $315.00 $1020.00 | 5 | |
CK-666 serves as an indirect inhibitor of Myocardin by targeting the actin cytoskeleton. As an Arp2/3 complex inhibitor, CK-666 disrupts actin polymerization, influencing Myocardin's nuclear translocation and activity. This interference alters Myocardin-mediated transcriptional regulation, thereby impacting cellular processes regulated by Myocardin-induced gene expression. | ||||||
SR 11302 | 160162-42-5 | sc-204295 | 10 mg | $350.00 | 28 | |
SR-11302 acts as an indirect inhibitor of Myocardin by modulating the MAPK pathway. As an AP-1 transcription factor inhibitor, SR-11302 interferes with c-Jun phosphorylation and dimerization, reducing its interaction with Myocardin. This modulation limits Myocardin's coactivation of AP-1-mediated transcription, influencing cellular processes governed by the MAPK/Myocardin regulatory axis. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $198.00 $650.00 | 16 | |
A83-01 functions as an indirect inhibitor of Myocardin by targeting the TGF-β/Smad2 pathway. By inhibiting TGF-β receptor type I (TGFBR1) activity, A83-01 interferes with Smad2 phosphorylation and nuclear translocation, reducing its interaction with Myocardin. This modulation limits Myocardin's coactivation of Smad2-mediated transcription, influencing cellular processes governed by the TGF-β/Smad2/Myocardin regulatory axis. | ||||||